J. Gries

发表

LINEAR MIXED-EFFECT MULTIVARIATE ADAPTIVE REGRESSION SPLINES APPLIED TO NONLINEAR PHARMACOKINETICS DATA

D. Verotta, J. Gries, 2000, Journal of biopharmaceutical statistics.

Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study

V. Soriano, D. Dieterich, D. Back, 2005, Antimicrobial Agents and Chemotherapy.

Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol.

V. D’Agati, P. Nelson, I. Gelman, 2003, The Journal of antimicrobial chemotherapy.

Off‐Label Use of Ketamine: A Challenging Drug Treatment Delivery Model With an Inherently Unfavorable Risk‐Benefit Profile

J. Gries, S. Pai, 2021, Journal of clinical pharmacology.

POPULATION PHARMACOKINETICS OF RITUXIMAB IN RA PATIENTS: COMBINING TWO PHASE II STUDIES PAGE 2005

B. Davies, M. Levi, C. Ng, 2005 .

Down-regulation models and modeling of testosterone production induced by recombinant human choriogonadotropin.

A. Munafo, D. Verotta, J. Gries, 1999, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy

T. Blaschke, L. Sheiner, K. Squires, 1997, Antimicrobial agents and chemotherapy.

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy

L B Sheiner, T F Blaschke, D Verotta, 1997, Antimicrobial agents and chemotherapy.

Modeling Nicotine Arterial–Venous Differences to Predict Arterial Concentrations and Input Based on Venous Measurements: Application to Smokeless Tobacco and Nicotine Gum

N. Benowitz, D. Verotta, S. Gourlay, 2002, Journal of Pharmacokinetics and Pharmacodynamics.

Peginterferon Alfa‐2a Does Not Alter the Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy

Sanjeev Arora, M. Sulkowski, J. Gries, 2005, Clinical pharmacology and therapeutics.

Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.

M. Narkewicz, K. Schwarz, S. Nash, 2006, Journal of pediatric gastroenterology and nutrition.

Safety, Efficacy and Pharmacokinetics of Peginterferon &agr;2a (40 kd) in Children With Chronic Hepatitis C

M. Narkewicz, K. Schwarz, S. Nash, 2006, Journal of pediatric gastroenterology and nutrition.

A descriptive tool to characterize nonlinear kinetics, with applications to meperidine and lidocaine.

R. Upton, D. Verotta, J. Gries, 1996, Journal of pharmaceutical sciences.

Blueprint for antibody biologics developability

J. Gries, Yanling Wang, C. Mieczkowski, 2023, mAbs.

RELATIONSHIP BETWEEN GRAFT CYTOCHROME P‐450 3A CONTENT AND EARLY MORBIDITY AFTER LIVER TRANSPLANTATION1

P. Beaune, F. Guengerich, H. Bismuth, 1993, Transplantation.

Chronopharmacokinetics of nicotine

D Verotta, D. Verotta, J M Gries, 1996, Clinical pharmacology and therapeutics.

Selecting Reliable Pharmacokinetic Data for Explanatory Analyses of Clinical Trials in the Presence of Possible Noncompliance

L. Sheiner, D. Verotta, Jianfeng Lu, 2001, Journal of Pharmacokinetics and Pharmacodynamics.

Incidence of adverse reactions to cyclosporine after liver transplantation is predicted by the first blood level

A. Lemoine, D. Azoulay, J. Gries, 1993, Hepatology.

Incidence of adverse reactions to cyclosporine after liver transplantation is predicted by the first blood level

P. Beaune, H. Bismuth, A. Lemoine, 1993, Hepatology.

A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS‐related complex

L. Sheiner, M. Jacobson, D. Verotta, 1997, Clinical pharmacology and therapeutics.

An innovative platform to improve asymmetric bispecific antibody assembly, purity, and expression level in stable pool and cell line development

C. Gustafsson, J. Minshull, Wenfeng Xu, 2022, Biochemical Engineering Journal.